Harnessing innovative neurotechnologies to provide better urgent care at Banner Health

For Banner Health, one of the largest non-profit health system in the United States, finding ways to make health care easier and better for our patients is at the root of everything we do. That’s why we are making significant investments into the digital health and neurotech space, trying to answer some common pain points.

Let me give you an example.

Last year, Banner Urgent Care turned to an innovative device, BrainScope One, to provide better care and to help save patients money and time, as it helps clinicians identify traumatic brain injuries and concussions.

This is an area of growing concern. Statistics by the Centers for Disease Control and Prevention (CDC) show that there were approximately 2.5 million visits to emergency departments for traumatic brain injuries in 2014—an increase of 54% from 2006. Of those, roughly 812,000 were for children.

BrainScope Advances its Commercial Adoption and Appoints Industry Veteran Susan Hertzberg as CEO

BETHESDA, MD. June 24, 2019 - BrainScope announced today the appointment of Susan Hertzberg as Chief Executive Officer.  This is the 4th equity-backed venture that Hertzberg will helm.  She is a proven commercial stage leader with an impressive track record of bringing innovative products and services to market and profitably scaling and delivering exceptional market growth. 

In her new role, Hertzberg will drive the global strategy and commercialization of BrainScope’s traumatic brain injury (TBI) and concussion tools in the traditional healthcare, military and sports arenas and will expand the platform capabilities of its signature product Brainscope One to include objective assessments for brain diseases like depression and Alzheimer’s.

“BrainScope is growing rapidly given the high demand and need for non-invasive, point of care FDA-Cleared medical devices to objectively assess concussion and mild TBI,” said Founding CEO Michael Singer, who will move into the Executive Chairman role. “I am thrilled to have Susan join us and apply her unique talents and experience to scale our business and make these tools ubiquitous in the market. Her mission-driven, patient-centric approach and dynamic leadership style is a great fit and will help BrainScope reach its full potential for this very large market opportunity,” added Singer.

AI Brain Device Reduces Need for CT Scans by Over 30 Percent

Traumatic brain injury (TBI) is a disturbance of normal brain functions due to a head injury that everyone is at risk. The Centers for Disease Control and Prevention (CDC) estimates that 138 people die each day in the U.S. due to injuries that include TBI. However, diagnosing TBI often involves unnecessary exposure to radiation from CT (computed tomography) scans. Recently published a few weeks ago in The American Journal of Emergency Medicine, a peer-reviewed publication, physicians at Washington University Barnes Jewish Medical Center in St. Louis found an over 30 percent reduction in unnecessary CT scans for TBI evaluations in emergency rooms using the recently FDA-approved medical device from BrainScope Company, Inc.—a medical neuro-technology company with various public sector and private sector funding, including venture capital from Revolution, founded by Steve Case, the co-founder of America Online (AOL).

Over 30% Reduction in Unnecessary Head CT Scans When Integrating FDA-Cleared BrainScope One

BETHESDA, MD. May 6, 2019 - BrainScope announced today the publication of a study conducted by physicians at Washington University Barnes Jewish Medical Center in St. Louis in the peer-reviewed journal The American Journal of Emergency Medicine entitled “Reduction in unnecessary CT scans head-injury in the emergency department using an FDA cleared device.” The study demonstrated that the FDA-cleared BrainScope One medical device reduced the use of unnecessary head CT scans by nearly one-third in a hospital emergency room setting when compared to the use of standard clinical practice.

Emergency Room (ER) visits for mild Traumatic Brain Injury (mTBI) have greatly increased due to increased awareness of potential consequences of such injuries, with roughly 5 million Americans seeking medical care for head injury in ERs each year. While the vast majority (>80%) of head-injured patients who go to the ER receive a head CT scan, more than 90% of them are found to be negative. This practice unnecessarily exposes these patients to radiation, increases the use of hospital ER resources, and lengthens throughput times.

Banner Health offers BrainScope in Northern Nevada

FERNLEY, Nev. (KOLO) Patients in northern Nevada can benefit from a new technology that allows for quicker assessments of head injuries, including concussions. Doctors at Banner Health Center in Fernley and Fallon are now offering BrainScope. The technology is a non-invasive, hand-held device used to make head injury assessments on site in non-emergency situations.

"It is a wonderful tool that will help us screen for the presence of concussions without necessarily having to send our patients for a cat scan or emergency room visit," Sharon Maxwell, a physician's assistant, says.

BrainScope Completes Large-Scale Clinical Studies of Concussion in Universities, High Schools and Concussion Clinics

BETHESDA, MD. March 28, 2019– BrainScope®, a medical neuro-technology company focused on concussion and mild traumatic brain injury (mTBI) assessment, announced today that it had concluded both algorithm development and clinical validation studies in adolescent and young adult populations using its objective, EEG-based technology. The purpose of the studies was to create and validate an objective, personalized capability for assessment of concussion and readiness to return to activities in males and females between the ages of 13-25. The studies conducted from 2015 through 2019 at 52 clinical sites included nearly 1,700 patients and healthy controls, with over 4,000 evaluations. Funding sources for the studies included a $9.9 million research contract from the U.S. Department of Defense, award funding from the NFL-GE Head Health Challenge (in which BrainScope was a two-time awardee), and BrainScope private funding.

“We are extremely pleased to have concluded these substantial clinical studies over 4 years, the results of which are extremely exciting as we work in the near-term through appropriate regulatory processes to bring important new concussion assessment capabilities to the market,” stated Michael Singer, CEO of BrainScope. “In particular I want to thank the U.S. Department of Defense, the NFL, GE, and BrainScope investors for their financial support of this major initiative which has yielded such excellent results.”

BrainScope Announces Publication Describing Proprietary Concussion Biomarker to Assess Potential Severity and Predict Prolonged Recovery

BETHESDA, MD. January 15, 2019– BrainScope®, a medical neuro-technology company focused on concussion and mild traumatic brain injury (mTBI) assessment, announced today that researchers have published preliminary results related to a multi-modal concussion assessment capability for potential severity and likelihood of prolonged recovery from concussions.  Published in the peer-reviewed journal Computers in Biology and Medicine, the paper entitled, “A multimodal biomarker for concussion identification, prognosis and management” describes a study which enrolled 568 concussed and matched control patients between the ages of 13-25 from 29 colleges and 19 high schools.  Subjects were tested at the time of injury and at multiple time points during recovery. 

Results from this study demonstrated highly significant differences in the BrainScope biomarker between the 177 concussed patients and controls at the time of injury and no significant differences at clinically determined Return-to-Play.  Progressive recovery over time was also demonstrated, especially in the prolonged recovery group.  Results also supported the hypothesis that some of the more severely injured subjects may have been allowed to return to play too soon. 

Point of Care Concussion Assessment on Your College Campus with BrainScope

As your student heads back to college, peace of mind should be at top of mind.

BrainScope is an accurate, cost-effective, radiation-free medical device, cleared by the FDA, that offers a full assessment of your head injury. BrainScope can assist your physician in making an objective decision on whether to send you to the ER, start treatment for a concussion, or send you home with a clean bill of health.

While not a replacement to CT, a BrainScope assessment can be done at a fraction of the cost of a CT, it can be done at your neighborhood doctor’s office, urgent care setting or yes, even in the ER!

Ask your doctor about BrainScope!

Assessment of the Full Spectrum of Brain Injury in the Emergency Department with BrainScope

Traumatic brain injuries including concussion are among the most common and challenging diagnoses for a physician to make in an Emergency Department, especially in patients presenting with mild head injuries. BrainScope gives Emergency physicians and staff greater assurance to rapidly and objectively assess the full spectrum of brain injury, including the likelihood of a structural component to the injury (one likely visible on CT) and the likelihood of a functional component to the injury (such as concussion).

Point of Care Concussion Assessment In Your Urgent Care with BrainScope

When patients hurt their heads, where do they go? Your urgent care can be an option. The revolutionary, EEG-based, BrainScope One head injury assessment device allows for assessment at the point of care. It provides economic value to your practice while delivering comprehensive, objective assessment results that help guide providers in the early intervention of both structural and functional injuries, including concussion, allowing for better outcomes and superior patient care.

The Economic Impact of BrainScope Head Injury Assessment System

The BrainScope system, utilizing Electroencephalogram (EEG) technology cleared by the FDA, is the first objective, adjunctive device capable of assessing the full spectrum of mild traumatic brain injury (mTBI). Its ability to rapidly identify the likelihood of both structural brain injury and functional brain abnormalities outside of the emergency room offers an opportunity for dramatic improvement to the current treatment path for evaluating mTBI patients.

The benefits could include diversion from the emergency department, a major reduction in unnecessary CT scans, and early intervention for patients with functional injuries, including concussion—contributing to the best possible outcomes in the shortest possible time.

BrainScope Receives FDA Clearance for Multi-Modal, Multi-Parameter Concussion Assessment

BETHESDA, MD. January 2, 2019– BrainScope®, a medical neuro-technology company focused on concussion and mild traumatic brain injury (mTBI) assessment, announced today that it has received FDA clearance to include additional language in its product’s Indications for Use (IFU), adding key terminology related to “multi-modal, multi-parameter assessment” of “concussion” and “mild Traumatic Brain Injury”, as well as an expanded and clarified overall IFU.  In addition to being able to objectively and reliably identify patients who may have a brain bleed using the product’s Structural Injury Classifier, BrainScope One uses the same electroencephalogram (EEG) signal and other capabilities on the device to objectively determine the likelihood of the presence and severity of a concussion.  All capabilities are summarized on a panel of multimodal, multi-parameter results, greatly facilitating clinical concussion assessment.

“This additional FDA labeling for our product, BrainScope One, recognizes the unique capabilities of our FDA-Cleared medical device with labeling distinctively and specifically for this particular disease state,” stated Michael Singer, CEO of BrainScope. “Years ago in working with our partner, the Department of Defense, we realized and learned from them the importance of multi-modality and objectivity.  Combining a full range of concussion assessment capabilities on one handheld platform provides the clinician a timely and easy-to-use tool for collecting the objective data they need to facilitate their clinical diagnosis, right then and there, for this debilitating brain disease state.”

Jordan Valley Health Clinic Using New Device to Evaluate Brain Injuries

SPRINGFIELD. Mo.--Jordan Valley Health Clinic is leading the charge in Springfield when it comes to properly  evaluating head injuries. The clinic is the only health care provider in the city to use a brainscope. 
    
Dr. Rafael Santiago-medical director for express care at Jordan Valley Health Clinic had athletes in mind when introducing the brainscope to the clinic.

"Say you're at a game right now you have a brain injury, you come to the express care, within 20-30 minutes, we're able to give you an answer with the status of your cognitive status. If you do require a CT scan because the brainscope tells you that you need a CT scan, then we refer you over to one of the area hospitals," says Dr. Santiago.

Ron Klain Joins BrainScope Board of Directors

BETHESDA, MD. December 11, 2018– BrainScope®, a medical neuro-technology company focused on concussion and mild traumatic brain injury (mTBI) assessment, announced today that Ron Klain, Executive Vice President and General Counsel of the investment firm Revolution, has joined BrainScope’s Board of Directors. 

Klain has served as Chief of Staff to U.S. Vice Presidents Joe Biden and Al Gore and Attorney General Janet Reno, was the White House Ebola Response Coordinator, and served as a Senior Aide to President Obama. He was also a Partner and National Practice Group Chair at O’Melveny & Myers LLP. He gained national notice as General Counsel for the Gore Recount Committee in 2000, in recognition of which he was selected as one of National Law Journal’s “Lawyers of the Year” and was featured in the HBO film Recount. Active in a number of civic and non-profit groups, he has served as Chairman of the Board of the Vice President’s Residence Foundation, and a member of the Board of Visitors of Harvard Law School.  He serves as a contributing columnist at The Washington Post.  Klain is a summa cum laude graduate of Georgetown University (where he serves as an Adjunct Professor) and holds a JD, magna cum laude, from Harvard Law School, where he was an Editor of the Harvard Law Review.  He follows in holding the BrainScope Board seat previously held by Jean Case.

Improved Assessment, Diagnosis and Management of Brain Injuries

Recent events have served as sad yet significant reminders of the seriousness of head injuries or traumatic brain injuries (TBIs).

As the football season ramped up, two tragic incidents took place in October alone. Christion Abercrombie, a linebacker for Tennessee State University, was rushed to the hospital and underwent life-saving emergency brain surgery after suffering a severe head injury. In Georgia, Pike County High School linebacker Dylan Thomas also sustained a severe head injury and was rushed to the hospital for surgery, but he tragically passed away soon afterwards.

The frequency and health risks of traumatic brain injuries, which include sports-related concussions, are increasingly being discussed and studied. As indicated in Table 1, there are close to 4 million sports-related concussions each year, with an additional 50% not being reported. The risks of not properly diagnosing and treating a brain injury are severe.

BrainScope Honors Veterans Day and Supports U.S. Army Deployment of Traumatic Brain Injury (TBI) and Concussion Assessment Devices

BETHESDA, MD. November 13, 2018– BrainScope®, a medical neuro-technology company focused on concussion and mild traumatic brain injury (mTBI) assessment, announced today that it has fulfilled orders for over 170 BrainScope One handheld devices and over 7,500 individual patient headsets to U.S. Army bases across the world. U.S. Army medics and clinicians continue to receive the training necessary to support the assessment of military personnel that may have experienced an mTBI, providing access for service members at home and abroad.

BrainScope Grand Rounds Series- Publication Navigator

The BrainScope One system provides objective data that helps clinicians answer two key questions in mildly presenting head-injured patients:

1. Is it likely that there is a structural brain injury that would be visible on a CT scan?

2. Is there evidence of functional brain impairment that could indicate a concussion?

The video below highlights a decade worth of research and development of the BrainScope One device. This includes 24 investigator-initiated publications describing clinical usability, the standard of care comparisons, and the validation of the BrainScope One algorithms.

Grand Round Videos Presented By Leslie Prichep, Ph.D Chief Scientific Officer, BrainScope Company Inc. Adjunct Professor, Department of Psychiatry New York University School of Medicine

The following four videos are intended to educate healthcare professionals on the fundamental scientific and clinical basis of the BrainScope One device. They are not intended to be a substitute for device labeling. Please consult with BrainScope for detailed device labeling such as Indications for Use and Instruction / Directions for Use.